← All trials
NCT06274294
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 10, 2024
- Primary completion
- Jan 31, 2025
- Completion date
- Jan 31, 2025
- First posted
- Feb 23, 2024
- Last posted
- Jul 31, 2024
- Enrollment
- 130
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- CHU AMBROISE PARELead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.